Jaguar Health, Inc. ( JAGX ) shares are falling Tuesday after the company announced its phase 3 OnTarget trial results for crofelemer did not meet its primary endpoint.

The Details:

Jaguar Health ( JAGX ) said the initial results from its OnTarget study for crofelemer show the multicenter, double-blind, placebo-controlled pivotal clinical trial did not meet its primary endpoint for the prespecified analysis of all tumor types in the trial. Crofelemer is an FDA-approved prescription drug for the symptomatic relief of diarrhea in adult HIV/AIDS patients receiving antiretroviral therapy. 

"We believe the OnTarget trial, designed boldly to address a broad array of cancer patients undergoing therapy known to be associated with diarrhea, did not meet the primary endpoint given the heterogeneous nature of the patients enrolled in the trial. Nevertheless, we are pleased that our preliminary analysis of the study data shows a clinically meaningful benefit in response to crofelemer in patients with breast and respiratory cancers, including lung cancer," said Lisa Conte, CEO of Jaguar.

Read Next: SunPower Stock Attempts To Bounce Back: What’s Going On?

Jaguar shares are dropping on heavy trading volume with more than 7.5 million shares already traded in Tuesday's session. According to data from Benzinga Pro, the stock has a float of only 4.889 million shares after having effected a 1-for-60 reverse split at the end of May. 

How To Buy JAGX Stock:

By now you're likely curious about how to participate in the market for Jaguar Health ( JAGX ) – be it to purchase shares, or even attempt to bet against the company.

Buying shares is typically done through a brokerage account. You can find a list of possible trading platforms here. Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, or Amazon.com, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so.

In the the case of Jaguar Health ( JAGX ), which is trading at $1.44 as of publishing time, $100 would buy you 69.44 shares of stock.

If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a stock can be found at this resource. Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading – either way it allows you to profit off of the share price decline.

JAGX Price Action: According to Benzinga Pro, Jaguar Health ( JAGX ) shares are down 56.2% at $1.87 at the time of publication Tuesday.

Read Also:

What’s Going On With Coinbase Shares Today?

Image: Mediamodifier from Pixabay